



Oncology in the Era of SARS-CoV-2

Guest Editors:

Dr. Konstantinos Syrigos

Third Department of Internal
Medicine, Sotiria Hospital,
National and Kapodistrian
University of Athens, School of
Medicine, 11527 Athens, Greece

Dr. Ioannis Vathiotis

Third Department of Internal
Medicine, Sotiria Hospital,
National and Kapodistrian
University of Athens, 11527
Athens, Greece

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editors

Dear Colleagues,

This Special Issue will focus on the impact of the SARS-CoV-2 pandemic in the care of patients with cancer covering aspects such as the epidemiology & management of SARS-CoV-2 infection in patients with malignancy, delayed diagnosis and management of the underlying malignancy, caveats in the design and conduct of clinical trials, running guidelines regarding the vaccination of patients with cancer, mRNA technology and its applications in cancer therapy and the application of the SARS-CoV-2 expertise in the development of novel antineoplastic drugs. Original research articles and reviews are welcome.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com